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Abstract: The evolution of antibiotic resistance among bacteria threatens our continued 
ability to treat infectious diseases.  The need for sustainable strategies to cure bacterial 
infections has never been greater.  So far, all attempts to restore susceptibility after 
resistance has arisen have been unsuccessful, including restrictions on prescribing [1] 
and antibiotic cycling [2,3]. Part of the problem may be that those efforts have 
implemented different classes of unrelated antibiotics, and relied on removal of 
resistance by random loss of resistance genes from bacterial populations (drift). Here, 
we show that alternating structurally similar antibiotics can restore susceptibility to 
antibiotics after resistance has evolved.  We found that the resistance phenotypes 
conferred by variant alleles of the resistance gene encoding the TEM β-lactamase 
(blaTEM) varied greatly among 15 different β-lactam antibiotics. We captured those 
differences by characterizing complete adaptive landscapes for the resistance alleles 
blaTEM-50 and blaTEM-85, each of which differs from its ancestor blaTEM-1 by four mutations.  
We identified pathways through those landscapes where selection for increased 
resistance moved in a repeating cycle among a limited set of alleles as antibiotics were 
alternated. Our results showed that susceptibility to antibiotics can be sustainably 
renewed by cycling structurally similar antibiotics. We anticipate that these results may 
provide a conceptual framework for managing antibiotic resistance.  This approach may 
also guide sustainable cycling of the drugs used to treat malaria and HIV. 
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Introduction: 
For the past seventy years, the world has been flooded with β-lactam antibiotics 
[4,5].  They have been the favored treatment for most bacterial infections because of 
their efficiency, specificity, and low toxicity [6,7]. In the 1940s and beyond, penicillin and 
penicillin derivatives were the most heavily used β-lactams [8].  However, specificity of 
penicillins for gram positive bacteria and increasing frequencies of β-lactamases in 
resistant bacteria spurred the development of extended spectrum β-lactams including 
cephalosporins, monobactams, and carbapenems in the 1980s [5]. Within a few years, 
resistance to those antibiotics also evolved and the frequencies of those resistance 
determinants have continued to rise [5,9].  Decreasing the consumption of β-lactams has 
not been successful in lowering resistance rates [1], nor has alternating (cycling) their 
use with unrelated (non β-lactam) classes of antibiotics [2,3].  However these attempts to 
control antibiotic resistance have included ad hoc selections of antibiotics, usually with 
no underlying theoretical or experimental framework.  
It is unfortunate that the development of the necessary theoretical and 
experimental underpinnings of successful antibiotic cycling lagged behind the efforts of 
the medical community.  However, theoretical and experimental work directed at this 
problem is starting to catch up.  Recommendations about how to derive  the optimal 
orders of antibiotics and the duration over which they should be applied have been 
introduced and are being refined [3,10,11,12].  It is fairly clear at this point that although 
clinical cycling may not be reliable yet, more informed and sophisticated models have 
the potential to make management of resistance by antibiotic cycling a robust approach 
to the resistance problem. 
We asked whether alternating the use of structurally similar antibiotics (all β-
lactams) might restore their usefulness.  We reasoned that when the selective pressure 
resulting from consumption of an antibiotic is removed from a population, either through 
cycling or decreased consumption, pleiotropic fitness costs associated with expression 
of the resistance mechanism will be the major selective pressure removing resistance 
determinants from bacterial populations.  If those fitness costs are extremely low, or if 
compensatory mutations have ameliorated their effects, such that there are essentially 
no fitness costs associated with expression of the resistance mechanism, then drift may 
be the major mechanism for removing those resistance determinants [13,14,15,16,17].	  
The enormity of bacterial populations and the impossibility of complete discontinuance of 
an antibiotic make removal of resistance by drift too slow a process to have any practical 
outcome.  Instead, we reasoned that if the selective pressure for the evolution of a 
specific resistance determinant could be in constant flux, then evolution would occur 
much more rapidly, and always have a moving target.  We wondered whether it might be 
possible to direct the evolution of resistance in a cyclical fashion. 
The experimental model we used to test this approach was the TEM family of β-
lactamases.  They are often the most frequently encountered resistance genes in clinical 
bacterial populations. Collectively they confer resistance to the majority of β-lactam 
antibiotics [9]. Over 200 unique variants of TEM that differ in amino acid sequence have 
evolved since the gene encoding  the TEM-1 β-lactamase (blaTEM-1) was first identified in 
1963 (http://www.lahey.org/Studies/). The consumption of the antibiotics responsible for 
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selecting those substitutions has been recorded 
[18,19,20,21,22,23,24,25,26,27,28,29,30,31,32].  
Results 
In this study, we have determined the topologies of adaptive 
landscapes[33,34,35,36,37,38,39,40,41,42,43,44,45,46,47] that were traversed as two 
blaTEM alleles evolved naturally. The genes blaTEM-50 [48]	  and blaTEM-85 [49]	  differ from their 
ancestor blaTEM-1 by four mutations that result in amino acid substitutions.  Those 
mutations have arisen independently multiple times during the course of blaTEM evolution 
[50] and confer adaptive benefits.  Although those mutations have adaptive roles in 
certain genetic backgrounds and selective environments, they are not always beneficial 
in every genetic background.  This phenomenon is called sign epistasis.  To characterize 
those landscapes, we created all possible combinations of the mutations found in blaTEM-
50 and blaTEM-85  (Table 1), and determined the resulting resistance phenotypes by disk 
diffusion testing with 15 β-lactam antibiotics (Table 2) that have been used heavily 
during the period in which TEM variants have arisen.  
 
We assumed the strong selection weak mutation (SSWM) model [51] as both 
alleles evolved; we also assumed that increased resistance indicates increased fitness 
[52].  We organized our results using fitness graphs (SI, Figures S1-S30) where 16 
nodes correspond to the 16 alleles. In principle, a fitness graph coincides with the 
Hasse-diagram of the power set of events wherein addition fitness differences between 
adjacent genotypes, ie genotypes that differ by one mutation, are indicated (see 
materials and methods).  Specifically, the wild-type allele (blaTEM-1) is at the bottom, 
alleles with single mutations are one level above, alleles with two mutations are at the 
next level, followed by those with three and then four mutations (ie blaTEM-50 and blaTEM-
85). Line segments drawn between adjacent nodes complete the graph. Green lines 
indicate selection for mutation, red lines indicate selection for reversion; absence of a 
line indicates that the adjacent nodes are phenotypically equivalent. We used one-way 
ANOVA testing to determine 95% confidence intervals around the mean resistance 
phenotypes and to assign direction. The fitness graphs reflect coarse properties of the 
fitness landscapes, including accessible trajectories, the number of peaks and sign 
epistasis. Such properties are important for our approach to drug cycling programs. 
However, since fitness graphs depend on fitness ranks of genotypes only, they will not 
reflect quantitative aspects which may be relevant for recombination. Fitness graphs 
reveal the adaptive potential under the assumption that no recombination, double 
mutations or other extreme genetic events take place. 
 
The Complexity of Fitness Landscapes 
Additive fitness landscapes have a single peak.  In contrast, random 
(uncorrelated or rugged) fitness landscapes have no correlation between the fitness of 
adjacent alleles. Random fitness and additivity can be considered as two extremes with 
regard to the amount of structure in the fitness landscapes. The degree of additivity, 
roughly how close the landscape is to an additive landscape, is of interest for comparing 
landscapes in different settings. Since we work with qualitative information we use the 
qualitative measure of additivity, a value ranging from 0 to 1 for fitness landscapes, 
where the value is 1 for additive landscapes and close to 0 for a random fitness 
landscape [53]. The mean values were 0.33 for TEM-50 and 0.57 for TEM-85, using the 
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landscapes where the measure applies. The complete statistics show that the TEM-85  
landscapes have considerably less additivity than for additive landscapes and 
considerably more additivity than expected for random fitness landscapes. The results 
for TEM-50 point in the same direction (see materials and methods). 
 In an additive landscape where TEM-85 confers the greatest fitness advantage, 
fitness should always increase with the addition of more mutations.  However, in the 
cefotaxime and ceftazidime landscapes where TEM-85 does confer the greatest fitness 
advantage, there are seven instances in each where fitness increases via reversion of a 
previously existing mutation. Overall, there are several occurrences of sign epistasis in 
14 out of 15 landscapes.  The cefoxitin landscape (Figure S26) has nearly no sign 
epistasis because it is almost flat, in the sense that there are no significant fitness 
differences for most alleles. For TEM-50 sign epistasis also occurred in 14 out of 15 
landscapes and the ampicillin landscape was flat (Figure S1). 
 
Adaptive trajectories in single-antibiotic and fluctuating environments 
 
TEM-50 landscapes 
In the 15 adaptive landscapes that include blaTEM-50 related alleles, there were no 
pathways containing consecutive increases of resistance between blaTEM-1 and blaTEM-50 
(See figures S1-S15).  Based on this result, it is possible that recombination occurred 
during the evolution of blaTEM-50.  However, an alternate explanation for the evolution of 
blaTEM-50 is fluctuation of environments as different antibiotic have been administered.  
When the results from the 15 different landscapes were simultaneously considered, we 
identified 5589 trajectories between blaTEM-1 and blaTEM-50.  
 
TEM-85 landscapes 
In contrast, two of the 15 adaptive landscapes that include blaTEM-85 related 
alleles contain pathways of consecutively increasing resistance between blaTEM-1 and 
blaTEM-85 (Figures S16-S30).  Cefotaxime (Figure 1a) and ceftazidime (Figure 1b) can 
individually select for the evolution of blaTEM-85 with either two or three pathways, 
respectively. TEM-85 is the allele of greatest fitness for both cefotaxime and ceftazidime.  
The cefotaxime landscape has 2 peaks and the ceftazidime landscape has 4 peaks. We 
computed the probabilities for a population going to fixation at TEM-85, rather than at 
suboptimal peaks, using a basic model which assumes that available beneficial 
mutations are equally likely to occur and go to fixation. For cefotaxime the probability for 
fixation at TEM 85 was 75%, and for ceftazidime 12.5%.  When all landscapes were 
simultaneously considered, which is appropriate under circumstances of fluctuating 
selection, we found 15,716 pathways between blaTEM-1 and blaTEM-85. 
  These results are consistent with Weinreich et al. [52] in that when a single 
environment is considered, there are few pathways through which evolution can 
proceed.  These results are also consistent with the study by Bergstrom et al. [3]	  in 
which they found that random fluctuations of antibiotics can accelerate the evolution of 
resistance. 
 
Antibiotic Cycles 
The complexity of the adaptive landscapes makes it possible to identify cycles of 
antibiotics that are likely to effectively manage resistance.  The somewhat frequent 
increases in resistance that result from reversions of mutations indicate that the 
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evolution of resistance is sometimes reversible.  Based on this observation we 
investigated approaches for cycling antibiotics as a method for managing resistance. We 
determined whether it was possible to cyclically restore susceptibility to a sequence of 
antibiotics by alternating exposure to those antibiotics as follows:  We first identified the 
alleles that were local optima in the presence of at least one antibiotic, and that were 
also adaptive valleys in the presence of at least one other antibiotic. Next we identified 
the antibiotic environments where those local optima and valleys exist.  We then 
identified pathways that formed closed loops within those adaptive landscapes; the 
pathways returned to the allele where they had begun. For blaTEM-50 landscapes the 
antibiotics we identified were cefepime,	  cefprozil, and ceftazidime  (Figure 2).  We found 
that 41,961 different cycles exist in those landscapes. For the blaTEM-85 landscapes, we 
identified the antibiotics cefprozil, ceftazidime, cefotaxime, and ampicillin as the most 
appropriate choices for antibiotic cycling and with those, we identified 1770 cycles 
(Figure S31). These results indicate that there are numerous routes for resistance to be 
reversed when those three antibiotics are cycled, which is an indication that this 
approach is robust.  If the order of antibiotics is perturbed, the effects of cycling those 
antibiotics should be consistent.  One caveat is that in the case of TEM-85, there are 
very few reversions that increase fitness when the allele blaTEM-85 has been reached 
(Figure S31), allowing the potential for “escape” from the cycling regimen.  Generating 
adaptive landscapes for more antibiotics may ameliorate this situation. 
 
Discussion 
Our results indicate that the occurrence of sign epistasis may provide a means 
for sustainably renewing the usefulness of antibiotics once resistance to them has 
evolved.  Historic failures of ad hoc cycling programs for antibiotics in hospitals have no 
bearing on our approach. The scheme for drug cycling we suggest relies on current 
laboratory techniques, as well as established theory of adaptation, and it remains to 
evaluate our approach in a clinical setting.  Our results indicate that abundant sign 
epistasis exists for the TEM resistance determinants and that it provides a means for 
sustainably renewing the usefulness of β-lactam antibiotics once resistance to them has 
evolved.  An obvious limitation in our approach is that we have considered only a few 
mutations associated with antibiotic resistance. For practical solutions, a more complete 
picture is required.  Other antibiotic cycling studies have added significantly towards our 
understanding of what factors will improve cycling.  A knowledge of pleiotropic fitness 
costs associated with resistance mechanisms can help to inhibit the evolution of multi-
drug resistant strains and possibly eliminate those that already exist.  The order and 
timing in which antibiotics are applied also have a significant effect on the occurrence of 
resistance. Additionally, a recent study that demonstrated the effectiveness of a program 
in which a hospital cycled among β-lactam antibiotics to reduce resistance over a period 
of several years [54].  This success is consistent with our results and may have 
benefitted in its design from the apparent absence of pleiotropic fitness costs associated 
with expression of most serine β-lactamases [55].  
 
Recommendations for further development of cycling  
It is likely that effective cycling programs will be specific to local environments 
and the specific resistance alleles in that environment.  The identification of an effective 
antibiotic cycling program will require identifying the resistance alleles currently 
circulating in the local environment, determining the fitness of each of those alleles with 
respect to the set of antibiotics being considered, then identifying those drugs that will 
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result in a repeating cyclic path through the local adaptive landscape.  Additionally, 
optimizing the order in which antibiotics are applied [11,12]	  and the duration for which the 
antibiotics are administered are key [3,10].   
The required experiments are neither difficult nor time consuming.  The analyses 
will be facilitated by user-friendly programs that are under development.  Although the 
introduction of unexpected novel alleles, either by mutation or from sources external to 
the local environment, may disrupt an effective cycling program, identification of those 
alleles and their addition to the analysis is likely permit effective modification of the 
cycling program.  Applying the suggested antibiotic cycling scheme will be made even 
more practical as it builds upon thorough analyses of many adaptive landscapes. 
Moreover, in pathogens such as malaria and HIV where fewer and more predictable 
resistance mechanisms exist, this method may be more easily implemented. 
 
 
Methods 
Mutants and Susceptibility Testing 
We used QuikChange® site-directed mutagenesis (Stratagene) to generate all 
mutant constructs from the blaTEM-1 gene in plasmid pBR322 (Table 1).  Those mutant 
alleles were expressed in Escherichia coli strain DH5-αE.  We performed Kirby Bauer 
Disk Diffusion Susceptibility testing [56] for 10 replicates of each of the 32 strains under 
15 commonly prescribed β-Lactam antibiotics (Table 2).  
Identifying Paths and Cycles 
In order to compute all possible combinations of pathways, we have represented 
the fitness graph of a drug as a possibly cyclic directed graph G = (N ,E) .  The nodes N  
of the graph represent the alleles, and the directed edges E  of the graph are 
determined by the statistical analysis of the resistance differences among alleles. Nodes 
ni ∈N  do not have costs associated to them, however costs are associated with each 
edge ei ∈E  and are determined by the resistance difference between the two nodes that 
are connected by the edge. 
Since we consider a biallelic system, the genotypes can be represented by a 
string of 0’s and 1’s, where the zero-string 0000 represents the wild-type. A fitness graph 
compares the fitness ranks of mutational neighbors. Roughly, consider the zero-string as 
the starting point and each non-zero position of a string as an event, i.e., that a mutation 
has occurred.  Under these assumptions the fitness graph coincides with the Hasse-
diagram of the power set of events, except that each edge in the Hasse-diagram is 
replaced with an arrow toward the string with greater fitness. 
For a formal definition, a fitness graph for a biallelic L-loci population is a directed 
graph where each node corresponds to a string (which represents a genotype). The 
fitness graphs has L +1  levels. Each string such that si∑ = l  corresponds to a node on 
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level l  in the fitness graph. In particular, the node representing the zero-string is at the 
bottom, the nodes representing strings with exactly one non-zero position are one level 
above, the nodes representing strings with exactly two non-zero positions are on the 
next level, and the 1-string is at the top. Moreover, the nodes are ordered from left to 
right according to the lexicographic order where 1 > 0 of the corresponding strings.  A 
directed edge connects each pair of nodes such that the corresponding strings differ in 
exactly one position. The edge is directed toward the node representing the more fit of 
the two genotypes. 
Fitness graphs reflect coarse properties of fitness landscapes, including sign 
epistasis. For a complete analysis of fitness landscapes other methods are necessary.  
The most fine-scaled approach to epistasis is the geometric theory of gene interaction 
[44].	   
 Once graph G = (N ,E)  is built and the edge costs are computed and associated 
with their corresponding edges, path queries in the graph can then be computed. To 
compute all the pathways, from the initial starting node (0000 in our trials), a search 
expansion is performed by adding each connected node as a child to the current node in 
a search tree representation.  Since backward edges are possible, a mechanism to 
detect cycles is included by making sure that expanded nodes do not appear twice in a 
pathway. When a cycle is detected, the last node of the cycle is not expanded. The 
overall expansion continues until all the search tree branches reach the target node 
1111. The final search tree will represent all possible pathways. 
 In addition to the search tree, we use a priority queue Q that maintains ranked all 
the current leaves of the search tree to be expanded. We use a Dijkstra-like cost-to-
come sorting function in Q, which represents the accumulated costs of the pathways 
since the source node. The priority queue ranks all available leaf nodes to be expanded 
and the node with lowest cost is always expanded first. This guarantees that each node 
is reached in the order of appearance in the shortest path from the source node to it. 
This guarantees that the shortest cycles are always found first. Since cycle 
determination is important in our research, all identified cycles are stored and saved for 
later analysis.  
 Although our experiments involved searches with different graphs (single or 
multiple drugs), searches with either forward or backward edges and searches with 
different starting nodes (1111 for backwards pathways), the described search method 
was the same and handled well all situations. The used notation in our figures shows 
backward edges in red and forward edges in green. 
Degree of additivity: 
The degree of additivity, roughly how close a landscape is to being a completely 
additive landscape, can be measured in different ways. We used the qualitative measure 
of additivity which ranges from 0 to 1 for fitness landscapes. For a formal definition:  The 
set Bp  consist of all double mutants such that both corresponding single mutations are 
beneficial. 
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 The set B⊆ Bp  consists of all double mutants in Bp which are more fit than at 
least one of the corresponding single mutants. 
The qualitative measure of additivity is the ratio B
Bp
. 
 B
Bp
= 1  for an additive landscapes.  For random fitness landscapes, the measure 
is expected to be close to zero in this setting. Indeed, using standard arguments in the 
Orr-Gillespie approach, the wild-type has very high fitness also in the new environment, 
in comparison with a randomly generated genotype. By definition, fitness is uncorrelated 
for a random fitness landscape, so that double mutants combining beneficial mutations 
are expected to be no more fit than randomly generated genotypes. It follows that the 
qualitative measure is close to zero, and a more precise estimate is that it should be less 
than 3% for random landscapes in this context. The derivation of this result will be 
published elsewhere.  The conclusion depends on an analysis of TEM data from the 
record of clinically found mutants. 
For the 15 TEM-85 landscapes,  the qualitative measure applies for 9 out of the 
15 landscapes.  The result is 0, 0, 0, 1/3, 5/6, 1, 1, 1, 1.  The mean value is 0.57. This 
result deviates considerably from expectations for additive and random landscapes. 
Indeed, if all landscapes were additive, the result should be 1 in each case modulo 
measurement errors. For random landscapes, non-zero values are expected to be rare.  
For TEM-50 the qualitative measure applies for 3 landscapes out of 15 and the 
corresponding data is 0,0,1.  The mean value is 0.33. From the qualitative measure 
alone, we have an indication that the landscapes are neither all additive, nor all random, 
also for TEM-50 (even if the data set is small).   
  The qualitative measure of additivity is useful for comparing a fitness landscape 
with other empirical landscapes, as well as with additive and random (or uncorrelated) 
landscapes. The measure is robust in the sense that small differences in the 
environment, such as (moderate) changes of the concentration of antibiotics, have no 
impact. Quantitative measures may be more sensitive. However, one should not over 
interpret the qualitative measure. This is a coarse measure, since it depends on fitness 
ranks only.  
 
Probabilities 
 By the SSWM assumption we were able to consider fixation of beneficial 
mutations as independent events. Therefore, we computed the probability for a trajectory 
as the product of the probabilities of its steps. The probabilities for single substitutions 
can be determined by the following well-established estimate: 
The probability that a beneficial mutation j will be substituted at the next step in 
adaptation is: 
 
s j
s1 + ...+ sk   
	   10	  
where sr  is the fitness contribution of mutation r  and where there are k  beneficial 
mutations in total. However, we used the simplified assumption that fitness is equal for 
available beneficial mutations, so that this probability equals 1k .   
	   11	  
 
References 
 
1. Andersson DI, Hughes D (2011) Persistence of antibiotic resistance in bacterial 
populations. FEMS microbiology reviews 35: 901-911. 
2. Brown EM, Nathwani D (2005) Antibiotic cycling or rotation: a systematic review of the 
evidence of efficacy. J Antimicrob Chemother 55: 6-9. 
3. Bergstrom CT, Lo M, Lipsitch M (2004) Ecological theory suggests that antimicrobial 
cycling will not reduce antimicrobial resistance in hospitals. Proc Natl Acad Sci U 
S A 101: 13285-13290. 
4. Livermore DM (1996) Are all beta-lactams created equal? Scand J Infect Dis Suppl 
101: 33-43. 
5. Shahid M, Sobia F, Singh A, Malik A, Khan HM, et al. (2009) Beta-lactams and beta-
lactamase-inhibitors in current- or potential-clinical practice: a comprehensive 
update. Critical reviews in microbiology 35: 81-108. 
6. Livermore DM (2005) Minimising antibiotic resistance. Lancet Infect Dis 5: 450-459. 
7. Matagne A, Lamotte-Brasseur J, Frere JM (1998) Catalytic properties of class A beta-
lactamases: efficiency and diversity [published erratum appears in 1998 May 
1;331(Pt 3):975]. Biochem J 330: 581-598. 
8. Mroczkowska JE, Barlow M (2008) Fitness tradeoffs in blaTEM evolution. Antimicrob 
Agents Chemother. 
9. Medeiros AA (1997) Evolution and dissemination of beta-lactamases accelerated by 
generations of beta-lactam antibiotics. Clinical Infectious Diseases 24: S19-45. 
10. Perron GG, Lee AE, Wang Y, Huang WE, Barraclough TG (2012) Bacterial 
recombination promotes the evolution of multi-drug-resistance in functionally 
diverse populations. Proceedings Biological sciences / The Royal Society 279: 
1477-1484. 
11. Beardmore RE, Pena-Miller R (2010) Rotating antibiotics selects optimally against 
antibiotic resistance, in theory. Mathematical biosciences and engineering : MBE 
7: 527-552. 
12. Beardmore RE, Pena-Miller R (2010) Antibiotic cycling versus mixing: the difficulty of 
using mathematical models to definitively quantify their relative merits. 
Mathematical biosciences and engineering : MBE 7: 923-933. 
13. Kimura M, Ohta T (1971) Protein polymorphsim as a phase of molecular evolution. 
Nature 229: 467-469. 
14. Kimura M, Ohta T (1969) The Average Number of Generations until Fixation of a 
Mutant Gene in a Finite Population. Genetics 61: 763-771. 
15. Kimura M (1983) The neutral theory of molecular evolution. New York: Cambridge 
University Press. 
16. Kimura M (1983) Neutral Theory. In: Nei M, Koehn R, editors. Evolution of genes and 
proteins. Sunderland, Mass: Sinauer Associates. 
17. Kimura M (1962) On the probability of fixation of mutant genes in a population. 
Genetics 47: 713-719. 
18. Coenen S, Ferech M, Dvorakova K, Hendrickx E, Suetens C, et al. (2006) European 
Surveillance of Antimicrobial Consumption (ESAC): outpatient cephalosporin use 
in Europe. J Antimicrob Chemother 58: 413-417. 
	   12	  
19. Ferech M, Coenen S, Dvorakova K, Hendrickx E, Suetens C, et al. (2006) European 
Surveillance of Antimicrobial Consumption (ESAC): outpatient penicillin use in 
Europe. J Antimicrob Chemother 58: 408-412. 
20. Ferech M, Coenen S, Malhotra-Kumar S, Dvorakova K, Hendrickx E, et al. (2006) 
European Surveillance of Antimicrobial Consumption (ESAC): outpatient 
quinolone use in Europe. J Antimicrob Chemother 58: 423-427. 
21. Ferech M, Coenen S, Malhotra-Kumar S, Dvorakova K, Hendrickx E, et al. (2006) 
European Surveillance of Antimicrobial Consumption (ESAC): outpatient 
antibiotic use in Europe. J Antimicrob Chemother 58: 401-407. 
22. (2003) National Nosocomial Infections Surveillance (NNIS) System Report, data 
summary from January 1992 through June 2003, issued August 2003. Am J 
Infect Control 31: 481-498. 
23. Fridkin SK, Steward CD, Edwards JR, Pryor ER, McGowan JE, Jr., et al. (1999) 
Surveillance of antimicrobial use and antimicrobial resistance in United States 
hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial 
Resistance Epidemiology (ICARE) hospitals. Clin Infect Dis 29: 245-252. 
24. Steward CD, Wallace D, Hubert SK, Lawton R, Fridkin SK, et al. (2000) Ability of 
laboratories to detect emerging antimicrobial resistance in nosocomial 
pathogens: a survey of project ICARE laboratories. Diagn Microbiol Infect Dis 38: 
59-67. 
25. Tenover FC, Raney PM, Williams PP, Rasheed JK, Biddle JW, et al. (2003) 
Evaluation of the NCCLS extended-spectrum beta-lactamase confirmation 
methods for Escherichia coli with isolates collected during Project ICARE. J Clin 
Microbiol 41: 3142-3146. 
26. Mendes RE, Castanheira M, Garcia P, Guzman M, Toleman MA, et al. (2004) First 
isolation of bla(VIM-2) in Latin America: report from the SENTRY Antimicrobial 
Surveillance Program. Antimicrob Agents Chemother 48: 1433-1434. 
27. Walsh TR, Toleman MA, Hryniewicz W, Bennett PM, Jones RN (2003) Evolution of 
an integron carrying blaVIM-2 in Eastern Europe: report from the SENTRY 
Antimicrobial Surveillance Program. J Antimicrob Chemother 52: 116-119. 
28. Bell JM, Turnidge JD, Gales AC, Pfaller MA, Jones RN (2002) Prevalence of 
extended spectrum beta-lactamase (ESBL)-producing clinical isolates in the 
Asia-Pacific region and South Africa: regional results from SENTRY Antimicrobial 
Surveillance Program (1998-99). Diagn Microbiol Infect Dis 42: 193-198. 
29. Bell JM, Turnidge JD, Jones RN (2002) Antimicrobial resistance trends in 
community-acquired respiratory tract pathogens in the Western Pacific Region 
and South Africa: report from the SENTRY antimicrobial surveillance program, 
(1998-1999) including an in vitro evaluation of BMS284756. Int J Antimicrob 
Agents 19: 125-132. 
30. Fedler KA, Biedenbach DJ, Jones RN (2006) Assessment of pathogen frequency 
and resistance patterns among pediatric patient isolates: report from the 2004 
SENTRY Antimicrobial Surveillance Program on 3 continents. Diagn Microbiol 
Infect Dis 56: 427-436. 
31. Moet GJ, Jones RN, Biedenbach DJ, Stilwell MG, Fritsche TR (2007) Contemporary 
causes of skin and soft tissue infections in North America, Latin America, and 
Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-
2004). Diagn Microbiol Infect Dis 57: 7-13. 
32. Bell JM, Chitsaz M, Turnidge JD, Barton M, Walters LJ, et al. (2007) Prevalence and 
significance of a negative extended-spectrum beta-lactamase (ESBL) 
	   13	  
confirmation test result after a positive ESBL screening test result for isolates of 
Escherichia coli and Klebsiella pneumoniae: results from the SENTRY Asia-
Pacific Surveillance Program. J Clin Microbiol 45: 1478-1482. 
33. Hartl DL, Dykhuizen DE, Dean AM (1985) Limits of adaptation: the evolution of 
selective neutrality. Genetics 111: 655-674. 
34. Dykhuizen DE, Dean AM, Hartl DL (1987) Metabolic flux and fitness. Genetics 115: 
25-31. 
35. Dykhuizen DE, Dean AM (2004) Evolution of specialists in an experimental 
microcosm. Genetics 167: 2015-2026. 
36. Dykhuizen DE, Dean AM (1994) Predicted fitness changes aloing an environmental 
gradient. Evol Ecol 8: 524-541. 
37. Dean JL, Wang XG, Teller JK, Waugh ML, Britton KL, et al. (1994) The catalytic role 
of aspartate in the active site of glutamate dehydrogenase. Biochem J 301: 13-
16. 
38. Dean CR, Visalli MA, Projan SJ, Sum PE, Bradford PA (2003) Efflux-Mediated 
Resistance to Tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1. 
Antimicrob Agents Chemother 47: 972-978. 
39. Dean AM, Dykhuizen DE, Hartl DL (1988) Fitness effects of amino acid 
replacememts in the beta-Galactosidase of Escherichia coli. MolBiolEvol 5: 469-
485. 
40. Dean AM, Dykhuizen DE, Hartl DL (1986) Fitness as a function of beta-
galactosidase activity in Escherichia coli. Genetical Research 48: 1-8. 
41. Dean AM (1995) A molecular investigation of genotype by environment interactions. 
Genetics 139: 19-33. 
42. Dean AM (1989) Selection and neutrality in lactose operons of Escherichia coli. 
Genetics 123: 441-454. 
43. Crona K, Greene D, Barlow M (2012) The peaks and geometry of fitness 
landscapes. Journal of theoretical biology 317C: 1-10. 
44. Beerenwinkel N, Pachter L, Sturmfels B, Elena SF, Lenski RE (2007) Analysis of 
epistatic interactions and fitness landscapes using a new geometric approach. 
BMC evolutionary biology 7: 60. 
45. Carneiro M, Hartl DL (2010) Colloquium papers: Adaptive landscapes and protein 
evolution. Proceedings of the National Academy of Sciences of the United States 
of America 107 Suppl 1: 1747-1751. 
46. Franke J, Klozer A, de Visser JA, Krug J (2011) Evolutionary accessibility of 
mutational pathways. PLoS computational biology 7: e1002134. 
47. de Visser JA, Park SC, Krug J (2009) Exploring the effect of sex on empirical fitness 
landscapes. Am Nat 174 Suppl 1: S15-30. 
48. Sirot D, Recule C, Chaibi EB, Bret L, Croize J, et al. (1997) A complex mutant of 
TEM-1 beta-lactamase with mutations encountered in both IRT-4 and extended-
spectrum TEM-15, produced by an Escherichia coli clinical isolate. Antimicrobial 
agents and chemotherapy 41: 1322-1325. 
49. Baraniak A, Fiett J, Mrowka A, Walory J, Hryniewicz W, et al. (2005) Evolution of 
TEM-type extended-spectrum beta-lactamases in clinical Enterobacteriaceae 
strains in Poland. Antimicrob Agents Chemother 49: 1872-1880. 
50. Barlow M, Hall BG (2002) Predicting evolutionary potential: in vitro evolution 
accurately reproduces natural evolution of the tem beta-lactamase. Genetics 160: 
823-832. 
	   14	  
51. Gillespie JH (1978) A general model to account for enzyme variation in natural 
populations. Theor Pop Biol 14: 1-45. 
52. Weinreich DM, Delaney NF, Depristo MA, Hartl DL (2006) Darwinian evolution can 
follow only very few mutational paths to fitter proteins. Science 312: 111-114. 
53. Crona K, Greene D, Barlow M (2013) The Peaks and Geometry of Fitness 
Landscapes. Journal of Theoretical Biology 317: 1-10. 
54. Sarraf-Yazdi S, Sharpe M, Bennett KM, Dotson TL, Anderson DJ, et al. (2012) A 9-
Year retrospective review of antibiotic cycling in a surgical intensive care unit. 
The Journal of surgical research 176: e73-78. 
55. Mroczkowska JE, Barlow M (2008) Recombination and selection can remove 
blaTEM alleles from bacterial populations. Antimicrobial agents and 
chemotherapy 52: 3408-3410. 
56. Institute CaLS (2008) Performance Standards for Antimicrobial Susceptibility 
Testing. 
 
 
  
	   15	  
Figure Legends 
 
Figure 1. Adaptive landscapes of TEM-85.  These diagrams show the pathways 
through which the blaTEM-85 can evolve in a single antibiotic. 
1a. (Left) The TEM-85 adaptive landscape in cefotaxime with pathways to TEM-85 
indicated. 
1b. (Right) The TEM-85 adaptive landscape in ceftazidime with pathways to TEM-85 
indicated. 
 Figure 2. Example of one possible outcome from antibiotic cycling.   
These diagrams show that by alternating the antibiotics cefepime, ceftazidime, and 
cefprozil susceptibility to those antibiotics can be restored in bacterial populations 
expressing variant alleles present in TEM-50 adaptive landscapes. 
2a. (Top left) The TEM-50 adaptive landscape in cefepime. Yellow peaks indicate the 
adjacent alleles that are important during cefepime selection. 
2b. (Top right) The TEM-50 adaptive landscape in ceftazidime.  Orange peaks indicate 
the adjacent alleles that are important during ceftazidime selection. 
2c. (Bottom left) The TEM-50 adaptive landscape in cefprozil. Red peaks indicate the 
adjacent alleles that are important during cefprozil selection. 
2d. (Bottom right) Composite cycle: The yellow arrow indicates the direction of selection 
in the presence of cefepime. The red arrows indicate the direction of selection in the 
presence of cefprozil.  The orange arrow indicates the direction of selection in the 
presence of ceftazidime. Rotation of these antibiotics results in cyclical renewal of 
antibiotic susceptibility. 
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Table 1. Constructs containing all possible combinations of the four mutations 
found in blaTEM-50 and blaTEM-85. 
Number of 
Substitutions 
Binary  
Allele 
Code  
Variants with 
mutations  found in 
blaTEM-50  
Variants of 
mutations  found in 
blaTEM-85 
0 0000 No Mutations No Mutations 
  TEM-1 TEM-1 
1 1000 M69L  L21F 
  (TEM-33) (TEM-117) 
1 0100 E104K   R164S 
  (TEM-17) (TEM-12) 
1 0010 G238S  E240K 
  (TEM-19) (Not identified) 
1 0001 N276D  T265M 
  (TEM-84) (Not identified) 
2 1100 M69L L21F 
  E104K  R164S 
  (Not identified) (TEM-53) 
2 1010 M69L L21F 
  G238S     E240K 
  (Not identified) (Not identified) 
2 1001 M69L L21F 
  N276D T265M 
  (TEM-35) (TEM-110) 
2 0110 E104K  R164S 
  G238S E240K 
  (TEM-15) (TEM-10) 
2 0101 E104K R164S 
  N276D T265M 
  (Not identified) (Not identified) 
2 0011 G238S  E240K 
  N276D T265M 
  (Not identified) (Not identified) 
3 1110 M69L  L21F 
  E104K R164S 
  G238S E240K 
  (Not identified) (TEM-102) 
3 1101 M69L L21F 
  E104K R164S 
  N276D T265M 
  (Not Identified) (Not identified) 
3 1011 M69L  L21F 
  G238S E240K 
  N276D T265M 
  (Not identified) (Not identified) 
3 0111 E104K  R164S 
  G238S E240K 
  N276D T265M 
  (Not identified) (Not identified) 
4 1111 M69L L21F 
  E104K R164S 
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  G238S E240K 
  N276D T265M 
  (TEM-50) (Not identified) 
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Table 2 The antibiotics used to characterize adaptive landscapes.  While not a 
comprehensive listing of all β-lactam antibiotics, this set contains many heavily used 
antibiotics and provides good general coverage of β-lactams. 
 
Antibiotic  FDA approval  Antibiotic Group  
Ampicillin (AM)  1963 Penicillin derivative 
Cefoxin(FOX)  1978 Cephalosporin 
Cefaclor(CEC)  1979 Cephalosporin 
Cefotaxime (CTX)  1981 Cephalosporin  
Ceftizoxime (ZOX)  1983 Cephalosporin   
Cefuroxime (CXM)  1983 Cephalosporin  
Ceftriaxone(CRO)  1984 Cephalosporin  
Amoxicillin +Clavulanic acid (AMC)  1984 Penicillin derivative + 
β-Lactamase inhibitor 
Ceftazidime (CAZ)  1985 Cephalosporin 
Cefotetan (CTT)   1985 Cephalosporin  
Ampicillin + Sulbactam (SAM)  1986 Penicillin derivative + 
β-Lactamase inhibitor 
Cefprozil (CPR)  1991 Cephalosporin   
Cefpodoxime (CPD)  1992 Cephalosporin 
Pipercillin + Tazobactam (TZP)  1993 Penicillin derivative + 
β-Lactamase inhibitor 
Cefepime(FEP)  1996 Cephalosporin  
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Supporting Information Legends 
Figures S1-S15 
Figures of TEM-50 Adaptive Landscapes  
Legend: Ovals represent alleles.  The names are given in binary code (See table 1). The 
absence of lines indicates no significant difference in resistance phenotypes.  Green 
lines indicate an increase in resistance resulting from addition of a mutation.  Red lines 
indicate an increase in resistance resulting from reversion. 
 
Figures S16-S30 
Figures of TEM-85 Adaptive Landscapes  
Legend: Ovals represent alleles.  The names are given in binary code (See table 1). The 
absence of lines indicates no significant difference in resistance phenotypes.  Green 
lines indicate an increase in resistance resulting from addition of a mutation.  Red lines 
indicate an increase in resistance resulting from reversion. 
 
Figure S31. Example of one possible outcome from antibiotic cycling. 
a. (Top left) Composite cycle: The red arrow indicates an allele (T265M) that will be 
selected by cefotaxime.  The green arrows indicate alleles that will be selected by 
ceftazidime.  The yellow arrow indicates alleles that will be selected by cefprozil.  
b. (Top right) The TEM-85 adaptive landscape in cefotaxime. Red peaks indicate the 
adjacent alleles that are important during cefotaxime selection. 
c. (Bottom left) The TEM-85 adaptive landscape in ceftazidime.  Green peaks indicate 
the adjacent alleles that are important during ceftazidime selection. 
d. (Bottom right) The TEM-85 adaptive landscape in cefprozil.  Yellow peaks indicate the 
adjacent alleles that are important during cefprozil selection. 
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Figure 1
 
Figure 2 
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Figure S1 TEM 50 Landscape for Ampicillin 
 
Figure S2 TEM 50 Landscape for Ceftazidime 
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Figure S3 TEM 50 Landscape for Cefaclor 
 
 
 
Figure S4 TEM 50 Landscape for Cefpodoxime 
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Figure S5 TEM 50 Landscape for Ceftriaxone 
 
Figure S6 TEM 50 Landscape for Cefprozil 
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Figure S7 TEM 50 Landscape for Cefotetan 
 
Figure S8 TEM 50 Landscape for Cefotaxime 
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Figure S9 TEM 50 Landscape for Cefuroxime 
 
 
Figure S10 TEM 50 Landscape for Cefepime 
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Figure S11 TEM 50 Landscape for Cefoxitin 
 
 
 
Figure S12 TEM 50 Landscape for Ceftizoxime 
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Figure S13 TEM 50 Landscape for Ampicillin + Sulbactam 
 
 
Figure S14 TEM 50 Landscape for Pipercillin + Tazobactam 
	   28	  
 
Figure S15 TEM 50 Landscape for Amoxicillin + Clavulanate 
 
 
 
Figure S16 TEM 85 Landscape for Ampicillin 
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Figure S17 TEM 85 Landscape for Ceftazidime 
 
 
 
 
 
Figure S18 TEM 85 Landscape for Cefaclor 
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Figure S19 TEM 85 Landscape for Cefpodoxime 
 
 
Figure S20 TEM 85 Landscape for Ceftriaxone 
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Figure S21 TEM 85 Landscape for Cefprozil 
 
 
Figure S22 TEM 85 Landscape for Cefotetan 
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Figure S23 TEM 85 Landscape for Cefotaxime 
 
 
Figure S24 TEM 85 Landscape for Cefuroxime 
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Figure S25 TEM 85 Landscape for Cefepime 
 
 
Figure S26 TEM 85 Landscape for Cefoxitin 
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Figure S27 TEM 85 Landscape for Ceftizoxime 
 
 
Figure S28 TEM 85 Landscape for Ampicillin + Sulbactam 
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Figure S29 TEM 85 Landscape for Pipercillin + Tazobactam 
 
 
Figure S30 TEM 85 Landscape for Amoxicillin + Clavulanate 
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Figure S31
 
	  
 
	  
